A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer

Gene Therapy

Volumn 17, Issue 11, 2010, Pages 1325-1332

  Trujillo, M A ^a   Oneal, M J ^a   McDonough, S ^a   Qin, R ^a   Morris, J C ^a  

^a MAYO CLINIC   (United States)

Author keywords

adenovirus; gene therapy; probasin; prostate cancer; sodium iodide symporter; virotherapy

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; IODINE 131; PROBASIN; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOLYSIS; CYTOPATHOGENIC EFFECT; DRUG UPTAKE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; TUMOR XENOGRAFT; VIROTHERAPY; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; MUS; MUS MUSCULUS; RICE STRIPE VIRUS;

EID: 78149471399     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.63     Document Type: Article

References (38)

1. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999; 20: 22-45.
2. Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neuro-Oncol 2004; 69: 101-117.
3. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001; 1: 130-141.
4. Yamamoto M, Curiel DT. Cancer gene therapy. Technol Cancer Res Treat 2005; 4: 315-330.
5. Carrasco N. Iodide transport in the thyroid gland. Biochimica et Biophysica Acta 1993; 1154: 65-82.
6. Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR et al. An immunohistochemical study of Na+/I-symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998; 139: 4416-4419.
7. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metabol Clinics North Am. 2007. 36. 807-822.
8. ELM. Carcinoma of follicular epithelium: Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD (eds). The Thyroid: A Fundamental and Clinical Text, 7th ed. Lippincott: Raven, Philadelphia, 1996: 922-945.
9. Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Therapy 2005; 12: 272-280.
10. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11: 1483-1489.
11. Dwyer RM, Bergert E R, O'Connor MK, Gendler SJ, Morris JC. Sodium Iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Therapy 2006; 13: 60-66.
12. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524-1531. (Pubitemid 33061890)
13. Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL et al. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radio-iodide imaging and therapy of locally recurrent prostate cancer. Mol Ther: J Am Soc Gene Ther 2005; 12: 835-841.
14. Morris JC./http://clinicaltrials.gov/ct/show/NCT00788307S 2009.
15. Herrmann F. Cancer gene therapy: principles, problems, and perspectives. J Mol Med 1995; 73: 157-163.
16. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573-587.
17. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
18. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603.
19. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002; 9: 961-966.
20. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 2008; 19: 873-886.
21. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312.
22. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
23. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141: 4698-4710.
24. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nuclear Med 2004; 45: 500-507.
25. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003; 63: 7840-7844.
26. Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003; 63: 5544-5550.
27. Humphreys MJ, Greenhalf W, Neoptolemos JP, Ghaneh P. The potential for gene therapy in pancreatic cancer. Int J Pancreatol 1999; 26: 5-21. (Pubitemid 29489581)
28. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-over-expressing breast and ovarian cancer. Adv Exp Med Biol 2000; 465: 171-180.
29. Miura Y, Ohnami S, Yoshida K, Ohashi M, Nakano M, Fukuhara M et al. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett 2005; 218: 53-62.
30. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208: 299-318.
31. Schmidt-Wolf G, Schmidt-Wolf IG. Human cancer and gene therapy. Ann Hematol 1994; 69: 273-279.
32. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N. The Na+/I-symporter of the thyroid gland. Soc Gen Physiol Ser 1993; 48: 251-262.
33. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 3422-3433.
34. Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ et al. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies meta-static potential. Prostate 2008; 68: 830-838.
35. Qu CF, Li Y, Song YJ, Rizvi SM, Raja C, Zhang D et al. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595radioimmunoconjugate. Br J Cancer 2004; 91: 2086-2093.
36. Anderson RD, Haskell R E, Xia H, Roessler BJ, Davidson BL. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Therapy 2000; 7: 1034-1038.
37. Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984; 114: 1090-1098.
38. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524-1531.